##semicolon##
моноклональные антитела, ревматология, ревматоидный артрит, псориатический артрит, системная красная волчанка, васкулит, безопасность, иммуногенность, биоаналоги, терапевтический лекарственный мониторинг.##submission.citations##
T. M. de Assis Damasceno, V. Fernandes, C. A. Leite da Silva, A. M. Candido da Silva, L. C. Ishikawa Cezar Santos, and V. Palmiro da Silva e Lima, “Storage Conditions of Immunobiologicals and their Influence on the Efficacy and Safety in the Treatment of Autoimmune Rheumatic Diseases”.// The Open Rheumatology Journal. // doi: 10.2174/187431290201401 0001.
V. D. Sokolova, V. V. Mladov, N. A. Sableva, and D. G. Tolkacheva. Эффективность биологических и таргетных синтетических базисных противовоспалительных препаратов, зарегистрированных в Российской Федерации для терапии взрослых пациентов с активным ревматоидным артритом: систематический обзор и сетевой метаанализ. //Med. Technol. Assess. Choice// , vol. 2022, no. 1, pp. 50–64, 2022, doi: 10.17116/med tech20224401150.
Jay Patel, Nithin Kumar Konanur Srinivasa, A. Gande, Madatala Anusha, Hassaan Dar. The Role of Biologics in Rheumatoid Arthritis: A Narrative Review. //Cureus. // 2023 Jan 3;15(1):e33293. doi: 10. 7759/cureus.33293.
Ali Berkant Avci 1, Eugen Feist 2, Gerd R Burmester. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned? // BioDrugs. //2023 Nov 21;38(1):61–71. doi: 10.1007/ s40259-023-00634-1.
Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. //Ann Rheum Dis. //2012;71(11):1839-1848.
Sayam Dubash, Charlie Bridgewood, Dennis McGonagle, Helena Marzo-Ortega. The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond. //Expert Rev Clin Immunol.// 2019 Feb;15(2):123-134. doi: 10.1080/ 1744666X.2019.1561281.
Estibaliz Lazaro, Marc Scherlinger, Marie-Elise Truchetet, Laurent Chiche, Thierry Schaeverbeke, Patrick Blanco, Christophe Richez. Biotherapies in systemic lupus erythematosus: New targets. //Joint Bone Spine. //2017 May;84(3):267-274. doi: 10.1016/j.jbspin.2016.07.004. Epub 2016 Sep 21.
Skopis M, Bag-Ozbek A. Maintenance with Rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. // Vessel Plus. // 2020; 4:30. https://dx.doi.org/10.20517/2574-1209.2020.42.
Elena Treppo, Marco Binutti, Roberto Agarinis,S alvatore De Vita, Luca Quartuccio Luca Quartuccio. Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives. // Clin. Med.// 2021, 10(17), 37 73; https://doi.org/10.3390/jcm10173773.
Maxim Eliseev, Evgeny Nasonov.Therapy with canakinumab for gout. April 2019. //Rheumatology Science and Practice // 56:41-48. DOI: 10.14 412/1995-4484-2018-41-48.
Al-Salama ZT. Secukinumab: A Review in Psoriatic Arthritis. //Drugs. //2021;81(4):467-478.
Selcan Demir, Hafize Emine Sönmez, Elif Arslanoğlu-Aydın, Seza Özen, Yelda Bilgine. Tocilizumab treatment in juvenile idiopathic arthritis patients: A single center experience. //Turk J Pediatr.// 2019;61(2):180-185. doi: 10.24953/ turkjped. 2019. 02.005.
Aaltonen KJ, Virkki LM, Malmivaara A, et al. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. // PLoS One.// 2012; 7(1):e30275.
L. Doessegger, M.L. Banholzer. Clinical development methodology for infusion-related reactions with monoclonal antibodies. // Clinical and Translational Immunology. // Volume: 4. DOI: 10.10 38/cti.2015.14.
Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, Ghogomu ET, Coyle D, Clifford T, Tugwell P, Wells GA. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. //Lancet. // 2015 Jul 18;386(9990):258-65. doi: 10. 1016/S0140-6736(14)61704-9.
Rindi LV, Zaçe D, Braccialarghe N, Massa B, Barchi V, Iannazzo R, Fato I, De Maria F, Kontogiannis D, Malagnino V, Sarmati L, Iannetta M. Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis. // Drug Saf. // 2024 Apr;47(4):333-354. doi: 10.1007/s40264-023-01383-4.
Gehin JE, Goll GL, Brun MK, Jani M, Bolstad N, Syversen SW. Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine.// BioDrugs. // 2022 Nov;36(6):731-748. doi: 10.1007/s40259-022-00559-1.
Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. // Ann Rheum Dis.// 2012 Nov; 71(11): 1914-5. doi: 10.1136/annrheumdis-2012-201544.
Krieckaert CL, van Tubergen A, Gehin JE et all. EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. //Ann Rheum Dis. // 2023 Jan;82(1):65-73. doi: 10.1136/ annrheumdis-2022-222155.
Puéchal X, M. C. Cost-effectiveness of rituximab as maintenance therapy for ANCA-associated vasculitis. // Ann Rheum Dis. //2019;78(9):1273-1279.
Wise LM, Stohl W. Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents. //Front Med (Lausanne).// 2020 Jun 30;7:303. doi: 10.3389 /fmed. 2020.00303.
Barszczewska O, Piechota A. The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab-Polish Experiences. // Int J Environ Res Public Health. // 2021 Jun 29;18(13):6952. doi: 10.3390/ ijerph18136952.
E. L. Nasonov, T. V. Korotaeva, T. V. Dubinina, A. M. Lila. IL-23/IL-17 inhibitors in immunoinflammatory rheumatic diseases: new horizons. // Rheumatology Science and Practice. //Vol. 57, no. 4pp. 400 – 406. doi.org/10.14412/1995-448 4-2019-400-406.